An Exploratory Study to Evaluate the Efficacy and Safety of the Cilostazol-coated BioMimics 3D Stent System in Patients with Peripheral Occlusive Arterial Disease
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 24
- 试验地点
- 5
- 主要终点
- Primary patency of stent at 12 months after the investigational procedure
研究概览
简要总结
An exploratory evaluation of the efficacy and safety of CLZ-BM3D for the treatment of symptomatic peripheral occlusive arterial disease of the superficial femoral artery or proximal popliteal artery
详细描述
This Study demonstrate an exploratory evaluation of the efficacy and safety of CLZ-BM3D for the treatment of symptomatic peripheral occlusive arterial disease of the superficial femoral artery or proximal popliteal artery
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with an ankle-brachial index (ABI) of 0.90 or less in the target lower extremity at rest.
- •Patients with stenotic lesions (target lesions) requiring treatment of SFA or PPA.
- •Patients with Rutherford classification 2, 3, or
- •The reference vessel diameter of the target lesion is between 4 mm or more and 5 mm by operator's visual estimate.
- •The total length of target lesion measure ≦50㎜ by operator's visual estimate.
- •Target lesion lumen stenosis is >70% diameter stenosis by operator's visual estimate.
排除标准
- •Patients with a history of surgical or endovascular treatment (including any percutaneous transluminal balloon angioplasty, stenting, atherectomy, or bypass) of the target lesion or vessel prior to enrollment in this study.
- •However, a history of balloon dilatoplasty with POBA is acceptable if it was performed earlier than 12 months prior to enrollment.
- •Patients with a history of major amputation of the target lower extremity.
- •Patients with another stenotic lesion in the target or contralateral lower extremity other than the target lesion that is judged to require surgery or endovascular treatment at the time of consent or within 12 months after the procedure.
- •However, if the patient has another stenotic lesion in the iliac artery other than the target lesion, treatment of the iliac artery lesion (POBA and stenting) is allowed at the time of the study procedure.
- •Patients with acute coronary syndrome or stroke/cerebrovascular event within 3 months prior to obtaining consent.
- •Patients with coagulopathy.
- •Patients with renal insufficiencyor on dialysis.
- •Patient who administered orally cilostazol within 7 days prior to the study procedure.
研究组 & 干预措施
CLZ-BM3D group
The cilostazol-coated BioMimics 3D stent on the delivery system is implanted into the target lesion and self-expands to maintain the vessel lumen diameter. Post-dilatation is performed as needed.
- CLZ is released from the surface of the implanted stent.
干预措施: Standard stenting (Device)
结局指标
主要结局
Primary patency of stent at 12 months after the investigational procedure
时间窗: 12 months
Loss of primary patency of the stent is determined as any of the following cases. * The case as the peak systolic velocity ratio (PSVR) exceeds 2.4 * The case as the subject had a CDTLR. * The case as the angiography revealed \> 50% lumen diameter stenosis.
Composite of major adverse events (MAEs) up to 12 months after the investigational procedure
时间窗: 12 months
MAE is defined as : * All death within 30 days after the study procedure. * Major amputation of target lower extrimity * Clinically driven target lesion revascurarization.
次要结局
未报告次要终点